
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>




































This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 16.8 kDa. The protein migrates as 20-27 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

Human TSLP Protein, His Tag, premium grade on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

Response to human TSLP protein (Fold).
The TSLPR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of Human TSLP Protein, His Tag, premium grade (AcroBiosystems, Cat. No. TSP-H52Hb). The max induction fold was approximately 45.15 (Routinely tested).

2e5 of Human TSLP R (Luc) HEK293 Reporter Cells were stained with 100 μL of 1 μg/mL of Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) and negative control protein respectively, washed and then followed by PE anti-His Tag Antibody and analyzed with FACS (Routinely tested).

Immobilized Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) at 0.5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human TSLP Antibody, Human IgG2 with a linear range of 0.2-4 ng/mL (QC tested).

Captured Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) on CM5 Chip via anti-His antibody, can bind Human TSLP R, Fc Tag (Cat. No. TSR-H525a) with an affinity constant of 1.81 nM as determined in SPR assay (Biacore T200) (Routinely tested).

Monoclonal Anti-Human TSLP Antibody (Human IgG2) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) with an affinity constant of 5.47 pM as determined in a SPR assay (Biacore T200) (Routinely tested).

Loaded Monoclonal Anti-Human TSLP Antibody, Human IgG2 on AHC Biosensor, can bind Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) with an affinity constant of 0.263 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Loaded Human TSLP R, Fc Tag (Cat. No. TSR-H525a) on Protein A Biosensor, can bind Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) with an affinity constant of 24.7 nM as determined in BLI assay (ForteBio Octet R8) (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Tezepelumab | AMG-157; MEDI-9929 | Approved | Amgen Inc | Tezspire | Japan | Asthma | Astrazeneca Kk | 2021-12-17 | Eosinophilic Esophagitis; Dermatitis, Atopic; Hypersensitivity; Pulmonary Disease, Chronic Obstructive; Bronchial Diseases; Hypersensitivity, Immediate; Sinusitis; Respiratory Hypersensitivity; Asthma; Lung Diseases, Obstructive; Immune System Diseases; Lung Diseases; Respiratory Tract Diseases; Nasal Polyps; Nose Diseases; Chronic Urticaria; Anaphylaxis; Carcinoma | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| AZD-8630 | AZD-8630; AMG-104 | Astrazeneca Plc, Amgen Inc | Details | ||
| BSI-045B | BSI-045B | Boaoxin Biotechnology(Nanjing) Co Ltd | Details | ||
| SAR-443765 | SAR-443765 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| MK-8226 | MK-8226 | Merck & Co Inc | Details | ||
| ASP-7266 | UPB-101; ASP-7266 | Phase 1 Clinical | Astellas Pharma Inc, Upstream Biosciences Inc | Asthma | Details |
| QX-008N | QX-008N; QX008N | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma | Details |
| HBM-9378 | SKB378; HBM-9378 | Phase 1 Clinical | Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Asthma | Details |
| GR-1802 | GR-1802 | Phase 2 Clinical | Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd | Asthma; Sinusitis; Dermatitis, Atopic | Details |
| Ecleralimab | CSJ-117; NOV-14 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| SHR-1905 | SHR-1905 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Asthma | Details |
| CM-326(Connaught Biomedical Technology) | CM-326 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Nose Diseases; Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
This web search service is supported by Google Inc.




